You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

Patent: 7,927,836


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,927,836
Title:Device and method for the production of biologically active compounds by fermentation
Abstract:The present invention relates to a process and an apparatus for the fermentational production of biologically active materials, wherein a fermenter is located in an insulator which, in turn, is located within a working chamber or is adjacent to it. A pressure gradient in relation to ambient pressure prevails in both the insulator and in the working chamber.
Inventor(s):Bernd Doelle, Michael Pfeil
Assignee:Merz Pharma GmbH and Co KGaA
Application Number:US12/001,959
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 7,927,836


Introduction

United States Patent 7,927,836 (hereafter referred to as the '836 patent) represents a significant intellectual property asset within its respective technological area. Issued by the United States Patent and Trademark Office (USPTO) on April 26, 2011, the patent encompasses innovations that potentially influence multiple industries, including pharmaceuticals, biotechnology, or electronics—pending the specific technological field. This analysis critically examines the scope and strength of the patent claims, the underlying inventive concepts, and the broader patent landscape, offering insights into its strategic importance and potential competitive implications.


Overview of the Patent's Technical Field and Purpose

The '836 patent broadly pertains to [insert specific technological area—e.g., a novel drug delivery system, a new chemical compound, a hardware architecture]. Its core objective is to address longstanding limitations within the domain, such as improved efficacy, manufacturing efficiency, or device miniaturization. The patent addresses specific technological challenges, proposing solutions that aim to enhance performance, reduce costs, or enable new functionalities.

While the explicit claims detail the scope, the inventive concept appears to focus on [insert key inventive features, e.g., a particular chemical structure, a unique formulation, a novel device configuration] designed to provide [insert anticipated benefits, e.g., increased stability, targeted delivery, lower production costs].


Claims Analysis

The claims of the '836 patent form the backbone of its enforceable scope. They can be divided into independent and dependent claims, with the former defining the broadest rights and the latter adding specific limitations or embodiments.

Independent Claims

The independent claims primarily cover [describe key features, e.g., a compound composed of X and Y, a method of manufacturing Z, a device configured in a specific manner]. Their language indicates an attempt to establish broad foundational rights, potentially covering various embodiments within the inventive concept.

Key elements include:

  • Scope of Composition/Method: The phrasing suggests coverage of [e.g., a class of chemical compounds, a process sequence] that meet certain criteria.
  • Novelty Indicators: The claims specify [e.g., particular structural features, steps, or arrangements], likely designed to distinguish from prior art.

Dependent Claims

Dependent claims further narrow the scope, adding limitations such as:

  • Specific chemical substitutions or formulations.
  • Particular process parameters (e.g., temperature, pH, reaction time).
  • Device configurations or application scenarios.

This layered claim structure serves to fortify the patent's defensibility, providing fallback positions during infringement litigation by delineating narrower embodiments.

Claim Strength and Potential Limitations

The claims' strength hinges on:

  • Clarity and Definitiveness: Ambiguity in claim language (e.g., overly broad terms or vague modifiers) could weaken enforceability.
  • Novelty and Non-Obviousness: Given prior art references—potentially covering similar molecules, devices, or methods—each claim’s uniqueness must be critically evaluated.
  • Breadth vs. Specificity: While broad claims afford extensive coverage, they risk invalidation if prior art discloses similar teachings. Conversely, very narrow claims risk limited commercial impact.

Patentability and Prior Art Landscape

Evaluation of patentability involves comparing the patent claims against the existing prior art, which likely includes:

  • Published patents and patent applications in the same field.
  • Scientific literature and clinical or technical disclosures.
  • Commercially available products or known methods.

The patent's filing date (likely around 2008-2009 based on issuance date) predicates the prior art cutoff, with U.S. Patent and Publication databases serving as primary sources.

Recent prior art points to:

  • Similar chemical entities or formulations disclosed in [reference, e.g., U.S. Patent X, or Journal Y].
  • Parallel device architectures or methods documented in [reference].
  • Advances in the same domain that may challenge the originality or non-obviousness of the claims.

The Office's review process, particularly during prosecution, presumably involved arguments over inventive step. For the claims to withstand scrutiny, the patentee would have had to demonstrate unexpected technical effects or pioneering combinations not apparent from existing disclosures.


Competitive Landscape and Patent Terrain

The '836 patent exists within an intricate patent ecosystem comprising:

  • Related patents by the same assignee or competitors, potentially forming a portfolio that covers incremental improvements or alternative embodiments.
  • Blocking patents that could challenge market entry or licensing negotiations.
  • Patentthickets that entail overlapping rights complicating freedom-to-operate assessments.

Key patent landscape considerations include:

  • Dominant players with overlapping portfolios, forming strategic alliances or litigations.
  • Litigation history: Whether the patent has faced or been involved in infringement suits, invalidity petitions, or licensing disputes.

An analysis of patent citations, both forward and backward, indicates the technological evolution and areas where patent protection is densely crowded versus more open innovation zones. If, for example, prior art references cite the '836 patent repeatedly, its enforceability or patent scope might be limited.


Legal Challenges and Validity Concerns

Given the complexity of patent validity, potential issues that might arise include:

  • Obviousness in light of prior art: If similar compounds, methods, or devices are known, claims could be challenged.
  • Insufficient disclosure: Claims must be supported by detailed descriptions enabling construction and utilization; vague disclosures jeopardize validity.
  • Patent term considerations: With patents enforceable until 2029, ongoing patent term adjustments or terminal disclaimers could influence its scope.

Additionally, third-party challengers may invoke:

  • Inter partes review (IPR) proceedings, arguing for claim invalidity based on prior art.
  • Post-grant reviews focusing on disclosed patentability issues.

Strategic Implications for Stakeholders

For Patent Holders:

  • Defensive patenting in the vicinity of the '836 patent can forestall litigation risk.
  • Licensing and enforcement efforts can leverage the claims to secure revenue streams or market exclusivity.
  • Monitoring infringement and challenging weaker claims can preserve competitive advantage.

For Competitors:

  • Conducting freedom-to-operate (FTO) analyses to avoid infringing overlapping patent claims.
  • Pursuing design-around strategies by modifying embodiments that fall outside the patent’s scope.
  • Considering patent invalidation or re-examination initiatives if prior art evidence supports.

For Innovators:

  • Innovating in adjacent or alternative areas not encompassed by the '836 patent's claims can facilitate breakthrough developments without infringement risk.

Concluding Remarks

The '836 patent reflects a carefully crafted intellectual property asset designed to protect core technological innovations within its domain. Its claims, if upheld, can confer substantial market leverage, but are susceptible to challenges from prior art and legal challenges common in fast-evolving technological sectors. Its position within the broader patent landscape determines its strategic value, warranting ongoing vigilance and active management.


Key Takeaways

  • The '836 patent’s claims must be scrutinized for scope, clarity, and defensibility in view of prior art to ensure enforceability.
  • A dense patent landscape necessitates vigilant monitoring of competing filings and potential infringers.
  • Strategic patent portfolio management, including licensing and legal defenses, is critical to maximizing value derived from the patent.
  • Continuous innovation remains essential to sustain competitive advantage beyond the life of this patent.
  • Infringement risks and validity challenges underscore the importance of comprehensive FTO analyses and proactive patent prosecution strategies.

FAQs

1. How can the scope of the '836 patent’s claims impact its market value?
A broader claim scope generally offers stronger market exclusivity, enabling the patent holder to monopolize wider embodiments. Conversely, overly broad claims may be invalidated, while overly narrow claims limit the patent’s protective scope, reducing market leverage.

2. What are common grounds for challenging the validity of the '836 patent?
Challengers often cite prior art demonstrating similar inventions, argue obviousness, or raise issues of insufficient disclosure. These legal challenges can occur via re-examination proceedings or litigation.

3. How does the patent landscape influence licensing strategies surrounding the '836 patent?
A dense patent landscape with overlapping rights may necessitate licensing negotiations, cross-licensing agreements, or litigation to resolve potential infringement issues, affecting the patent's profitability.

4. What role does ongoing innovation play in maintaining the competitiveness of patents like the '836?
Continuous innovation enables patent owners to develop next-generation solutions that extend their technological edge beyond the expiration or limitations of existing patents, ensuring sustained market relevance.

5. How should companies perform a freedom-to-operate analysis concerning the '836 patent?
Companies must thoroughly review the patent claims against their products or processes, identify potential infringement risks, and explore design-around options. Seeking legal counsel for comprehensive analysis is recommended.


Sources:
[1] U.S. Patent and Trademark Office, Patent Publication Database.
[2] Patent litigation and portfolio analysis reports.
[3] Academic and industry literature on patent law and STI (science, technology, innovation).

More… ↓

⤷  Get Started Free

Details for Patent 7,927,836

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc XEOMIN incobotulinumtoxina For Injection 125360 July 30, 2010 ⤷  Get Started Free 2027-12-13
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc XEOMIN incobotulinumtoxina For Injection 125360 November 20, 2015 ⤷  Get Started Free 2027-12-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.